Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Tretinoin may help cells that are involved in the body's immune response to work
better. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving
tretinoin together with interleukin-2 may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well giving three different doses of
tretinoin together with interleukin-2 works in treating patients with stage IV kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Chiron Corporation National Cancer Institute (NCI) National Institutes of Health (NIH)